A Phase 4 interventional study of Standard inactivated influenza vaccine (NH formulation) and MF 59 adjuvanted inactivated influenza vaccine (NH formulation) in Influenza, Human, sponsored by The University of Hong Kong. Completed at 1 site in China. Open to participants aged 65 Years to 82 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-15.
Sponsored by The University of Hong Kong · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing MF59 in Influenza, Human — 3 open to participants now, 3 under way, 1 of them phase 3. MF59 · Influenza, Human.
Among the 22 studies testing MF59 in Influenza, Human, this one is the 5th largest by enrollment, is one of 4 that started in 2017, is one of 3 in phase 4, and was the 16th registered.
2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.
Browse Influenza, Human studies →3 of the 22 studies testing MF59 in Influenza, Human are open now, in 1 country. Recruiting first, the newest first:
Korea University Guro Hospital · Sites in Korea, Republic of
Ages 19+ · Healthy volunteers
Asan Medical Center · Sites in Korea, Republic of
Ages 19+
National Taiwan University Hospital
Ages 50+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.
This study: 65 Years to 82 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 10 · Phase 4 3
First in 2006; this study’s year is marked. 4 started in 2017.
This study's enrollment of 1,861 is above the median of 228 across 1,959 interventional studies indexed under Influenza, Human.
Median enrollment 549 across the 22 interventional studies. Of the 19 that completed or were terminated, 10 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 22 have an industry lead sponsor. The 10 most frequent:
The University of Hong Kong is the lead sponsor of 1,295 studies on the registry; 351 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
22 studies in Influenza, Human by The University of Hong Kong: 1 open now, 3 under way, none of them phase 3. Of 12 finished, 0 (0%) have results posted.
Among the 22 studies in Influenza, Human by The University of Hong Kong, this one is the 4th largest by enrollment of the 20 interventional ones that give a count, is the only one that started in 2017, is one of 8 in phase 4, and was the 15th registered.
The University of Hong Kong’s Influenza, Human studies by the year they started, since 2008.
2 of the studies testing MF59 in Influenza, Human that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07485855Phase 3Asan Medical CenterInfluenza Vaccination Strategy for Patients With Hematologic Malignancy | 2027-04-30 |
| NCT07126652National Taiwan University HospitalSerological Responses to Adjuvanted Versus Non-adjuvanted Influenza Vaccines Among People With HIV: a Randomized Clinical Trial | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies testing MF59 in Influenza, Human, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among The University of Hong Kong’s 22 in Influenza, Human:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study allows to evaluate the strength and duration of immune responses between annual receipt of standard inactivated vaccine and alternative potent vaccines, including annual receipt of adjuvanted inactivated vaccine, annual receipt of high-dose inactivated vaccine, annual receipt of recombinant HA vaccine, and the alternate combinations of the former three vaccines over four years, for identifying improved vaccination strategies for influenza vaccination in older adults in a location experiencing a subtropical pattern in influenza activity.
Background: The typical vaccination strategy of annual administration with inactivated trivalent influenza vaccine (TIV) or quadrivalent influenza vaccine (QIV) may provide suboptimal protection to older adults in a location with prolonged periods of influenza activity because of the weaker immune response of older adults to vaccination and because of post-vaccination waning in protection over the course of a year. We hypothesize that in a subtropical or tropical location with prolonged circulation of influenza viruses, the higher antibody titers over years achieved after receipt of annual high-dose vaccine, MF59-adjuvanted vaccine or recombinant haemagglutinin (HA) vaccine, or different vaccination strategies of their combinations with or without the standard vaccine, might lead to greater protection than annual receipt of standard vaccines.
Aim: To test the immune profiles over time of older adults following different influenza vaccination strategies.
Design and subjects: Initially a 4-year immunogenicity study with a randomized controlled design among 2200 older adults aged 65-82 years. We will enroll participants who are willing to receive annual influenza vaccination from the general community including community centres and day-care centres. Eligible individuals will be randomly allocated to ten intervention groups (i.e. annual standard QIV, annual MF59-adjuvanted TIV, annual high-dose TIV, annual recombinant-HA QIV, and six combinations of their alternate annual use) consisting of four rounds of vaccination before each winter influenza season and followed up for 4 years. For each round of vaccination, blood samples for immunological tests will be collected before vaccination and 30 and 182 days after vaccination in all participants, and also at 7, 91 and 273 days after vaccination in a subset of 10% of the participants. Acute illnesses among participants will be monitored by active surveillance efforts during influenza seasons. The vaccine formulation in each round of vaccination will be updated for each season according to WHO recommendations.
Study extension: In years 5-8, all participants will receive the recombinant-HA QIV once per year before each winter influenza season, and their receipt of COVID-19 vaccines will also be recorded. Samples will be collected at the same timepoints to monitor immune responses to influenza vaccination and how responses are affected by prior vaccination history.
Main outcome measures: Antibody titers measured by haemagglutination-inhibition assays, which is an established correlate of protection, in addition to other measurements on humoral and cell-mediated immune responses in the ten intervention groups each year.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Individuals who report medical conditions not suitable to receive inactivated influenza vaccines, such as:
Individuals, who report medical conditions not suitable to receive intramuscular injection, such as:
Once-annual administration of standard vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
Biological: Standard inactivated influenza vaccine (NH formulation)
Alternating once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
Biological: Standard inactivated influenza vaccine (NH formulation) · Biological: MF 59 adjuvanted inactivated influenza vaccine (NH formulation)
Alternating once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
Biological: Standard inactivated influenza vaccine (NH formulation) · Biological: MF 59 adjuvanted inactivated influenza vaccine (NH formulation)
Alternating once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
Biological: Standard inactivated influenza vaccine (NH formulation) · Biological: High-dose inactivated influenza vaccine (NH formulation)
Alternating once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
Biological: Standard inactivated influenza vaccine (NH formulation) · Biological: High-dose inactivated influenza vaccine (NH formulation)
Alternating once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
Biological: MF 59 adjuvanted inactivated influenza vaccine (NH formulation) · Biological: High-dose inactivated influenza vaccine (NH formulation)
Alternating once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
Biological: MF 59 adjuvanted inactivated influenza vaccine (NH formulation) · Biological: High-dose inactivated influenza vaccine (NH formulation)
Once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
Biological: High-dose inactivated influenza vaccine (NH formulation)
Once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
Biological: MF 59 adjuvanted inactivated influenza vaccine (NH formulation)
Once-annual administration of recombinant hemagglutinin inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
Biological: Recombinant hemagglutinin inactivated influenza vaccine (NH formulation)
Alternating once-annual administration of recombinant hemagglutinin inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
Biological: MF 59 adjuvanted inactivated influenza vaccine (NH formulation) · Biological: Recombinant hemagglutinin inactivated influenza vaccine (NH formulation)
0.5mL FluQuadri®, Sanofi Pasteur, containing 60μg antigen - 15μg for each influenza strain included - with strains recommended by the WHO for the northern hemisphere formulation.
0.5mL FLUAD(TM), Seqirus containing 45μg antigen; 15μg for each influenza strain included and MF59C.1 adjuvant (MF59®) with strains recommended by the WHO for the northern hemisphere formulation.
0.5mL Fluzone® High-Dose, Sanofi Pasteur containing 180μg antigen; 60μg for each influenza strain included with strains recommended by the WHO for the northern hemisphere formulation.
0.5mL Flublok®, Protein Sciences Corporation containing 180μg antigen, 45μg for each influenza strain included with strains recommended by the WHO for the northern hemisphere formulation.
Difference in antibody titres
The difference in antibody titres of participants measured by haemagglutination-inhibition (HAI) assay, evaluated by (1) the proportion of participants who achieve a target rise in antibody titre against each of the vaccine strains at 30 days, and (2) the geometric mean titre (GMT) ratios between the two groups against each of the vaccine strains at 30 days and 182 days. (The targeted rise in antibody titre is defined as the percentage of subjects with either a pre-vaccination HAI titre \<10 and a post-vaccination HAI titre ≥40, or a pre-vaccination HAI titre ≥10 and a minimum four-fold rise in post-vaccination HAI antibody titre.)
Time frame: 30 and 182 days after each vaccination
Seroprotection
The proportion of participants who achieve seroprotection defined as an HAI titre ≥40 after each vaccination before the winter seasons.
Time frame: 30 days after each vaccination
CMI responses
The vaccine-induced influenza-specific CD4+ and CD8+ T cell responses 7 days post- vaccination, proxy by anti-viral IFNγ production evaluated by Intracellular Cytokine Staining (ICS) assay. Responses for these and other relevant biomarkers are compared to baseline at the time of vaccination.
Time frame: . 7 days after each vaccination
Adverse events
The rate of adverse events within 30 days after vaccination for each round of vaccination.
Time frame: 30 days after each vaccination
PCR confirmed infection
The rate of PCR-confirmed influenza infection in each round of the study.
Time frame: 182 days after each vaccination
Plan to share: Yes
Ran from Oct 2017 to primary completion in Dec 2025, 98 months.
Of 101 non-industry phase 4 interventional studies under Influenza, Human, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 52. This study's 98 months is above that.
Counting every sponsor, half of 138 studies reached it within 14 months; a quarter within 3 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MF59